 Hey guys, how are you doing? This is your boy Rich from Rich TV Live, and you can join the club at richpictaili.com where you too can learn how to win in the markets. We've got some big breaking news that we're gonna break for you right here, right now, only on Rich TV Live, Pharma there, PHRM, PHRRF. Here it is, you can see the symbol PHRM, PHRRF, Pharma there enters into research collaboration agreement with revive therapeutics for development of psilocybin, micro needle patch, big breaking news and focusing on partnership model for micro dose, MN trademark and macro dose, MN trademark patches to deliver psychedelics, creating value and intellectual property protection for psychedelic programs, providing pathways for partners to enter FDA phase one and two clinical studies in 2022 with psychedelics. This is the big breaking news for pharma there holdings limited. The big breaking news for pharma there holdings limited, a clinical stage psychedelics biotech company is pleased to announce it has entered into a research collaboration agreement with revive therapeutics, revive therapeutics on the OTCQB exchange under the symbol RVVTF in Canada on the Canadian security exchange under the symbol RVV and in Frankfurt, Germany under the symbol 31R, a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders to evaluate the delivery of psilocybin with pharma there's proprietary micro needle MN patch technology for neuro psychiatric disorders. Guys, we brought you guys pharma there first they've been a big winner for our community. They've been very volatile as well like all psychedelic stocks that come up and down. We will look at the chart of pharma there and revive. I just wanna go through the news and make sure everybody's aware of it because this is some very big news. Pharma there is currently conducting IND enabling research studies with micro dose MN trademark, a patent pending biocompatible and biodegradable gelatin, methacrylolial micro needle patch to deliver psilocybin to support an IND application with the FDA for clinical studies in 2022. Research results with micro dose MN trademark for psilocybin will be made available in November, 2021 which is right now. The company is also conducting research studies with its micro dose MN trademark and macro dose MN trademark patch as a next generation delivery system for psychedelics with ketamine, three and four, methylenedoxylamide, methamphetamine, MDMA, lysergic acid, diethanilamine, LSD, and NN demyndium T. So let's just, some hard words to say, we're gonna use the words MDMA, LSD and DMT. Also the company has decided to expand research to include ibogaine and mescaline. Partnership opportunities currently exist with MDMA, LSD, DMT, ibogaine and mescaline for specialty pharmaceutical companies seeking a differentiated and validation and validated delivery system for psychedelics. Desired pharma-co-kinetic profiles, intellectual property protection, CGMP microneedle patches for IND enabling and clinical studies and a clear pathway towards FDA phase one and two clinical studies in 2022. The company's micro dose MN trademark and macro dose dash MN trademark patches have the potential to efficiently penetrate the stratum, corneum layer, outer layer of the skin enabled flexible drug load capacity and combinations and control release delivery which may overcome the potential drawbacks of oral administration, subconscious injections, topical and nasal delivery systems in addition to the potential of maintaining constant plasma levels for more than 24 hours, the MN patches aim to empower patients to dose their medication remotely, safely, conveniently rather than under supervision by a healthcare provider at a certified medical office. To achieve this, the company will incorporate anti-tampering and anti-abuse features that would parallel the approach used for the tamper resistant, transdermal, fentanyl patch. We are pleased to collaborate with Revive in achieving their product portfolio objectives with psilocybin, our microneedle patch technologies aim to become next generation delivery system for psychedelics for various indications and healthcare environments. Although our focus remains on building our ketamine based product pipeline, we will continue to partner with specialty pharmaceutical companies seeking a delivery solution for psychedelics and proprietary drugs to unlock significant value and return on investment for a pharma there, said Fabio Cianelli, CEO of Pharma there. Michael Frank, CEO of the company commented, our focus is developing and commercializing a specialty psilocybin based product portfolio and to research collaboration with Pharma there, compliments our psilocybin product offering as potential treatment for mental illness, substance abuse and neurological disorders. We believe that there is no one fits all product profile solution with psilocybin. Let me reiterate that. We believe that there is no one fits all product profile solution with psilocybin for psilocybin to be a next generation therapeutic different use and delivery forms will be required to achieve the intended target indications as such we aim to become a leader in psilocybin based solutions for unmet medical needs by collaborating with companies that have intellectual property and experience in their delivery techniques such as Pharma there. What do you guys think about this partnership? Revive therapeutics and Pharma there. Revive is a life sciences company focused on the results research and development of therapeutics for infectious disease and rare disorders. And it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as orphan drug fast track, breakthrough therapy and rare pediatric disease designations currently the company is exploring the use of Bucillamine for the potential treatment of infectious disease with an initial focus on severe influenza and COVID-19 with its acquisition of psilocybin Pharma corp. Revive is advancing the development of psilocybin based therapeutics in various diseases and disorders. Revive cannabinoid pharmaceutical portfolio focuses on rare inflammatory disease and the company was granted FDA orphan drug status designation for the use of cannabinoidial CBD to treat autoimmune hepatitis liver disease and to treat eschema and reperfusion injury from organ transplantation. For more information, you can go to revivethera.com. Now let's tell you a little bit about Pharma Thera Holdings. We brought you guys Pharma Thera first. The been a big winner for our community. Congratulations to investors. Pharma Thera Holdings Limited, PHRRF in America. PHRM in Canada is a clinical stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics such as ketamine to treat mental health, neurological and pain disorders. Pharma Thera is currently advancing an FDA approved phase two clinical study with ketamine to treat Parkinson's disease and is developing a novel micro needle patch for the intradermal delivery of psychedelics and infectious disease treatments. You can go to pharmathera.com and see their website. You can follow them on Twitter. You can follow them on LinkedIn and we've gone through all of their different platforms that you can review and watch them on. So once again, the big news, Pharma Thera enters into a research collaboration agreement with Revive Therapeutics for the development of psilocybin micro needle patch. So the big news, now let's just go through the charts. I'm gonna share my screen with you right now and we're gonna go through the charts. So first and foremost, the first chart you see here is Pharma Thera PHRM and you can clearly see that we had our buy zone here at 20 cents. They went all the way up to a high of $1.23 where hopefully investors locked in profits and then they've come all the way back down. So this is extremely, extremely volatile. You can see that it's made this big move up where it was a five bagger from 20 cents to $1.20 and now it's made this move down where it's given back a lot of those gains and it's all the way back down to now 45 cents. So like all psychedelic stocks, it's been extremely volatile, had some good moves up and just recently taken this move back down. So the question is, where does it go from here? So this is the symbol in Canada, PhRRF is the symbol in America, looks a lot of the same as you can see here, made us move up and then came back down. And like all psychedelic stocks, they've been really struggling because they are all lacking in revenue and revenue growth and the street wants to see revenue. Now let's take a look at revive therapeutics. This is their one-year chart. So you can see that they've been pretty choppy, a lot of up and down movement. You can see here that they have trended up. RVV is a symbol in Canada and RVVTF in America. So they have been trending up despite the fact that they've been extremely choppy. And a lot of this is due to the fact that these companies are really lacking in revenue. If and when we see these companies grow their revenues, then I think we could see them really expand and grow and maintain a higher share price. But this news is the type of news that can help them get closer to revenue. Once again, pharma there enters into a research collaboration agreement with revive therapeutics for the development of psilocybin microneedle patch. What do you guys think of this news? What do you guys think about these videos? If you like this news, please smash the like button, comment down below, share the video everywhere and subscribe. Remember Rich TV Lab is strictly for information and education purposes. Please do your due diligence, do your research before you invest anything that we talked about here on Rich TV Live. And let's just take a look at these two websites. So pharmathera.com. All right, so this is the pharmathera.com website where you can do your research and learn more about this up and coming small cap company and revivethera.com. And this is revivethera.com. So this is the revive therapeutics website and this is a big, big, big deal for the sector, for the psychedelic sector. And like I said to you guys, we're strictly for information education purposes. We love to bring you the news, we love to break it down and make sure that you understand exactly what's going on. So once again, this is the big breaking news today. Pharmathera Holdings, PHRM in Canada, PHRF in America, a clinical stage, psychedelics biotech company is pleased to announce it's entered into a research collaboration agreement with revive therapeutics, a specialty life science company focused on the research and development of therapeutics for medical needs and rare disorders to evaluate the delivery of psilocybin with pharmathera's proprietary micro needle patch technology for neuro psychiatric disorders. What do you guys think of this news? Love to know, please comment down below, share the video everywhere and subscribe. Take a look at revive therapeutics website, take a look at pharmathera's website and we're gonna be watching these stocks very closely all day today. Let me know what you guys think. Are you buying these stocks? Do you hold these stocks? Are you thinking about positioning yourself in these companies? Let me know what you think. Is your boy rich from Rich to be live? Told you guys, if you're not winning, you're probably not watching. We bring in the winners, we bring in the news, we break down the deals and we do it first. Thank you guys for watching. Is your boy rich from Rich to be live and join the club at richpictailie.com where you two can learn how to become a profitable trader. What do you guys think of this news? Could be a catalyst for the sector, could be a catalyst for pharmathera and revive therapeutics. Thank you guys for watching. If you're not winning, you're probably not watching. We bring in the winners, we bring in the news and we bring it to you first. Thank you for watching everybody. Have a great day. Is your boy rich from Rich to be live and richpictailie.com and I'm out. Peace. It's big news. It's true.